Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease

Pharmacotherapy

Volumn 19, Issue 2, 1999, Pages 150-156

  Taylor, Anne C ^a   Beerahee, Almisbah ^a   Citerone, David R ^a   Cyronak, Matthew J ^a   Leigh, Terry J ^a   Fitzpatrick, Katherine L ^a   Lopez Gil, Arturo ^a   Vakil, Sarosh D ^a   Burns, Eileen ^a   Lennox, Graham ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; ROPINIROLE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; FEMALE; HUMAN; MALE; PARKINSON DISEASE;

AGED; ANTIPARKINSON AGENTS; AREA UNDER CURVE; CARBIDOPA; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 0032913543     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.3.150.30927     Document Type: Article

References (18)

1. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977;12:345-9.
2. Rajput AH, Rozdilsky B, Rajput A, Ang L. Levodopa efficacy and pathological basis of Parkinson syndrome. Clin Neuropharmacol 1990;13:553-8.
3. Sweet RD, McDowell FH. Five years' treatment of Parkinson's disease with levodopa. Ann Intern Med 1975;83:456-63.
4. Lesser RD, Fahn S, Snider SR, et al. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979;29:1253-60.
5. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-8.
6. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease; a five year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034-8.
7. 2 agonist. Pharmacol Biochem Behav 1991;38:147-54.
8. Taylor AC, Beerahee A, Citerone DR, Miller A, Fuell D. Linear pharmacokinetics of ropinirole in patients with Parkinson's disease. Br J Clin Pharmacol 1998;45(2):240P.
9. Cedarbaum JM. Clinical pharmacokinetics of amiparkinsonian drugs. Clin Pharmacokinet 1987;13:141-78.
10. Vickers S, Stuart EK, Hucker HB. Further studies on the metabolism of carbidopa, (-)-L-α-Hydrazino-3,4-dihydroxy-a-methylbenzenepropanoic acid monohydrate, in the human, Rhesus monkey, dog and rat. J Med Chem 1975;18:134-8.
11. Vickers S, Stuart EK, Bianchine JR, et al. Metabolism of carbidopa [L-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid monohydrate], an aromatic amino acid decarboxylase inhibitor, in the rat, dog, Rhesus monkey, and man. Drug Metab Dispos 1974;2:9-22.
12. Bloomer JC, Clarke SC, Chenery RJ. In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. Drug Metab Dispos 1997;25:840-4.
13. Brefel C, Thalamus C, Rayet S, et al. Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. Br J Clin Pharmacol 1998;45:412-15.
14. Evans MA, Broe GA, Triggs EJ, Cheung M, Creasey H, Paull PD. Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology 1981;31:1288-94.
15. Hardie RJ, Malcolm SL, Lees AJ, Stern GM, Allen JG. The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br J Clin Pharmacol 1986;22:429-36.
16. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism. Drugs 1976;11:329-77.
17. Beerahee A, Nichols AI, Aluri J, et al. Population pharmacokinetics of ropinirole in patients with Parkinson's disease. Br J Clin Pharmacol 1997;43:556P-7.
18. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35-49.